Organization, Nature of Business, and Liquidity (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($) Women	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Product Women Segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Organization and Nature of Business [Abstract]
Number of operating segments | Segment			1
Number of products that received EU MDR and CE certification marks | Product			4
Number of women using FemBloc for permanent birth control | Women	401		401
Duration of time women used FemBloc as permanent birth control			1 year
Number of women enrolled for a clinical readout | Women			50
Minimum number of subjects needed for Interim analysis of clinical data endpoints | Women			300
Period for analysis of clinical data for permanent birth control			1 year
Follow-up period for interim analysis of clinical data for permanent birth control			5 years
Liquidity [Abstract]
Cash and cash equivalents | $	$ 7,611,210		$ 7,611,210		$ 21,716,077
Net loss | $	(5,408,860)	$ (3,996,905)	(13,692,944)	$ (9,836,670)
Accumulated deficit | $	$ (122,074,573)		$ (122,074,573)		$ (108,381,629)